Background: Yellow fever virus (YFV) is a positive sense singlestranded RNA virus that is transmitted by mosquitoes and is endemic in the tropical regions of Africa and South America. The World Health Organization has estimated the annual prevalence of yellow fever to be 200 000 cases, of which more than 90% is attributed to Africa. Although highly efficacious live attenuated vaccines are available, use of the vaccines in immunocompromised individuals are contra-indicated and, although rare, vaccineassociated viscerotropic adverse events have been reported. Hence development of a safer alternative that can complement the use of the live vaccines would have application. The aim of this study was to prepare a DNA-launched Sindbis based replicon encoding the ED-lll protein of YFV and to characterize the expression of the ED-lll protein in transfected cells prior to evaluation as a candidate vaccine in an animal model.
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Background: The WHO has prequalified a killed oral cholera vaccine (OCV) in 2011, which has been a key measure in facilitating its use as part of a comprehensive package including water and sanitation measures to cholera epidemic affected areas such as Guinea and Haiti. A recent phase 3 trial enrolling approximately 70,000 adults and children in India demonstrated a 65% cumulative protective efficacy over 5 years. This is the first trial to evaluate the safety and immunogenicity of a two dose OCV regimen in an African population. The vaccine has been evaluated in a large number of human subjects in India, Vietnam, and Bangladesh, where it has demonstrated safety, immunogenicity, and clinical protective efficacy. Though we do not expect the vaccine to act differently in the Ethiopian population, we aim to confirm our understanding of OCV use in healthy individuals aged 1 year and above in Africa.
Methods & Materials: This was an individually randomized, controlled, double blinded, placebo controlled trial in 216 subjects, equally divided among healthy children and adults. Participants received two doses of vaccine or placebo. Blood was drawn to measure vibriocidal antibody response before the first dose (day 0), before the second dose (day 14), and on day 28.
Results: Preliminary unblinded safety data suggests that the vaccine is safe, with only 8 adverse events (AE) for both vaccine and placebo groups. All AEs were mild, self resolved, and were not clustered following either dose. Full analysis is to be completed in March, 2014, at which time results comparing vaccine to placebo recipients for safety and vibriocidal response will be available. This serves as an important step towards a mass vaccination demonstration project, aimed to strengthen national cholera surveillance. These findings, alongside concurrent efforts in other high risk regions, can pave the way for the integration of OCV in both endemic and outbreak settings in Ethiopia, Africa and beyond.
Conclusion: Adverse reactions were observed with similar frequency among vaccine and placebo recipients in both age groups. Adverse events (AE) were reported within 28 days of any dose in 0% and 1.8% of vaccinees and 5.6% and 1.8% of placebo recipients in adults and children respectively. All AEs were mild and self resolving. A robust immune response against Vibrio cholerae O1 was observed, with an 81% and 77% seroconversion rate in adults and children. These findings, alongside concurrent efforts in other high risk regions, can pave the way for the integration of OCV in both endemic and outbreak settings in Ethiopia, Africa and beyond. As the WHO and partners work to create an international stockpile, safety and immunogenicity data outside of Asia will be support-
